Oral Solid Dosage Pharmaceutical Market
Oral Solid Dosage Pharmaceutical Market Analysis By Dosage Form (Tablets, Capsules, Powders & Granules, Gummies, Lozenges & Pastilles) By Drug Release Mechanism (Immediate, Delayed & Controlled Release) By Distribution Channel & Region – Global Market Insights 2022 to 2032
Analysis of Oral Solid Dosage Pharmaceutical market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Oral Solid Dosage Pharmaceutical Market Outlook (2022 to 2032)
The global oral solid dosage pharmaceutical market was valued at US$ 524.6 billion in 2021 and is expected to top US$ 1.03 trillion in value by the end of 2032, expanding rapidly at a CAGR of 6.4% over the 2022 to 2032 study period.
Revenue from the sales of oral solid dosage pharmaceuticals accounted for 23.8% share of the global pharmaceutical drug delivery market in 2021.
| Data Points | Market Insights |
|---|---|
| Oral Solid Dosage Pharmaceutical Market Size (2021) | US$ 524.6 Billion |
| Estimated Market Value (2022) | US$ 555.3 Billion |
| Forecasted Market Value (2032) | US$ 1.03 Trillion |
| Global Market Growth Rate (2022 to 2032) | 6.4% CAGR |
| East Asia Market Share (2021) | 14.6% |
| East Asia Market Growth Rate (2022 to 2032) | 7.4% CAGR |
| China Market Growth Rate (2022 to 2032) | 8.3% CAGR |
| Share of Top 5 Countries | 62.1% |
| Key Market Players | AstraZeneca Plc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Gilead Sciences; Merck & Co. Inc; Novartis AG; Pfizer Inc.; AbbVie Inc.; Boehringer Ingelheim GmbH; Hoffman-La-Roche Ltd.; Johnson & Johnson; Biogen Inc.; Bayer AG; Teva Pharmaceuticals; Amgen Inc.; Takeda Pharmaceutical Company Ltd.; Otsuka Pharmaceutical Co., Ltd.; Astellas Pharma Inc.; Others |
Oral solid dosage pharmaceuticals are final medication products that are consumed orally, broken down in the digestive tract, and then absorbed into the bloodstream. Oral solid doses are less expensive and simpler to produce than other dosage forms. They also provide important advantages such as trouble-free transport, packaging, and greater chemical & physical stability.
Low production cost is also contributing to market growth, especially in developing nations such as India due to collaborations with small-scale and medium-scale manufacturers. The production cost of oral solid dosage pharmaceuticals is low in India due to low and competitive land rates, availability of cheap labor, low-cost utilities, and affordable equipment. In developing regions, the labor cost is approximately 60% lower than in developed countries.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Oral Solid Dosage Pharmaceutical Demand Analysis (2012 to 2021) Compared to Market Outlook (2022 to 2032)
The global oral solid dosage drugs market expanded at a CAGR of 5.8% over the last nine years.
Manufacturers are involved in developing new oral solid formulations of drugs to improve drug efficacy and enhance outcomes. New formulation designs are preferred by leading manufacturers for implementing a patient-centric approach to efficiently improve solid oral dosage formulation (SODF) administration in older patient populations.
Rise of usability and patient compliance is also a key aspect driving global demand for oral solid dosage medications and this is a key concern for drug producers. Modified release (MR) oral solid dosage solutions are experiencing a sharp increase in demand due to growing patient-centric drug demand.
By sustaining therapeutic blood concentrations for a longer period, modified release medications can prolong the time a medicine is active in the body. It is possible to postpone the effect until a medication reaches a particular location by using unique coatings.
There is a large number of products in the pipeline in the form of oral solid dosages with improved efficacy and outcomes. Various research institutions and companies are involved in the drug discovery process to expand the market for oral solid dosage pharmaceuticals.
- For instance, Assembly Biosciences sponsored “A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults” for chronic Hepatitis B. This was in phase 1 of clinical trials as of January 2021.
Similarly, there are many other studies taking place related to oral solid dosage medicines to develop better drugs for various disease conditions. When these studies become successful and gain approval for commercialization, they will benefit companies by adding new segments to portfolios and generating more revenue.
Fact.MR, a market research and competitive intelligence provider, predicts that the global oral solid dosage pharmaceutical market will expand at a CAGR of 6.2% over the forecast period (2022 to 2032).
What’s Mainly Driving Demand for Oral Solid Dosage Pharmaceuticals?
“Ease of Administration and Improved Patient Compliance”
Oral solid dosage pharmaceuticals are very convenient dosage forms with excellent bioavailability. Few oral solid dosage forms such as chewable tablets are gaining popularity at a high pace because they are user-friendly and convenient alternatives to conventional tablets. These have various other advantages such as less pain, ease of ingestion, and variety in accommodating various types of drugs.
Patient compliance, non-invasiveness, and ease of drug administration are factors that make oral solid dosage the most preferred dosage form. It is most commonly used for those conditions where the drug needs to be administered repeatedly and for a prolonged period. Apart from convenience and affordability, it is the safest form of drug dosage.
Manufacturers of oral solid drugs can attain considerable bioavailability by implementing cutting-edge drug delivery technology methods. For instance, tailored drug delivery and dose forms with prolonged release increase the bioavailability of medications and decrease the need for repeated medication administration.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
How is Oral Solid Dosage Pharmaceutical Market Growth Being Stunted?
“Difficulty in Oral Delivery Biologics Limiting Market Growth”
Currently, biologics are one of the most promising candidates for therapy, but their delivery is difficult due to the size of their large and complex molecules. There are various challenges in the oral delivery of solid dosage drugs. The most prominent challenge of biologics oral delivery is the harsh acidic environment of the gastrointestinal tract, which contains enzymes intended to break down molecules.
In addition, biologics or macromolecules have to pass multiple layers lining the track to reach the systemic distribution, which results in a lower bioavailability of drugs. Demand for macromolecular drugs such as biologics is increasing rapidly with the increasing prevalence of chronic diseases such as diabetes.
Apart from this, low R&D expenditure in low- and middle-income countries is also restricting the growth of the market. High-income countries have realized the importance of R&D and have invested enormously in the sector. Emerging nations, however, are still far behind in recognizing the potential advantages that R&D could provide for economic expansion and national advancement.
- According to a research article in Frontiers in Research Metrics and Analytics forum, global R&D spending was US$ 1.7 trillion in 2019. Around 80% of this share comes from just ten countries.
Country-wise Insights
What is the U.S. Market Stance for Oral Solid Dosage Pharmaceuticals?
The U.S. accounted for 93.6% of the North American oral solid dosage pharmaceutical market share in 2021 owing to the increasing number of oral solid dosage drug approvals in the country.
Approvals by the U.S. FDA are increasing and resulting in more products being launched, making the U.S a high revenue-generating country.
- For instance, The U.S. Food and Drug Administration (FDA) authorized 48 new medicines in 2019. 54% of these new FDA-approved medications were oral solid dosage products. It constituted 19 in the pills form and 7 in the capsules form.
Also, the rise in awareness about health supplements, which generally come in tablets or capsules, offers lucrative opportunities for the U.S. market for oral solid dosage pharmaceuticals.
Why is Germany a Lucrative Market for Oral Solid Dosage Drugs?
Germany accounted for 19.9% share in the Europe oral solid dosage pharmaceutical market in 2021.
Heart disease is one of the leading causes of death in Germany. Oral solid dosages are most commonly used for the treatment of heart diseases - use of Lotensin - benazepril (Rx) for the management of high blood pressure.
- According to the World Health Organization, circulatory diseases accounted for 37% of all deaths in Germany in 2019.
What are the Factors Fueling Demand for Oral Solid Dosage Solutions in China?
China accounted for 51.4% of the East Asia oral solid dosage pharmaceutical market at the end of 2021.
China provides medicines at very low prices due to the cost-effective drug production in the country. Low production cost is possible because top pharmaceutical companies have lowered the cost of drugs in China by an average of 61%. This is primarily due to the revised reimbursement scenario in the country.
For instance, pharmaceutical companies such as Roche and Novartis have decided to lower the cost of several of their newest medications in China. This helps the country in selling a high number of drugs to patients and increasing its presence in the global market.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Insights
Why is Demand for Tablets So High?
By dosage form, tablets accounted for the highest market share of 53.1% in 2021. The segment is expected to expand at 7.1% CAGR over the forecast period.
The most popular form of an oral solid dose is a tablet. These are affordable, secure, and efficient means of delivering oral medications, which is why their demand is so high in the market.
Which Drug Release Mechanism is Most Common in the Market?
By drug release mechanism, immediate release contributed the highest market share of 57.9% in 2021. The segment is expected to expand at 6.1% CAGR over the decade.
Immediate release tablets/capsules held the highest market share in 2021 because these are used to release the medication for absorption and subsequent pharmacologic action. It results in quick action and early pain relief.
Competitive Landscape
Key manufacturers of oral solid dosage pharmaceutical products are actively focusing on the expansion of their portfolios by gaining approvals for their new products and entering into partnerships with leading companies.
- In March 2022, AstraZeneca received clearance from the EU government for selling Evusheld long-acting antibody combinations for the prevention of COVID-19 in a broad population.
- In June 2022, Bristol Myers Squibb announced a definitive merger agreement for acquiring Turning Point Therapeutics. This acquisition will improve the oncology medicines segment of BMS because Turning Point Therapeutics is a clinical-stage precision oncology company.
Similarly, recent developments related to companies manufacturing oral solid dosage pharmaceuticals have been tracked by the team at Fact.MR, which are available in the full report.
Key Segments in Oral Solid Dosage Pharmaceutical Industry Research
-
By Dosage Form :
- Tablets
- Conventional/Immediate Release
- Modified Release
- Chewable Tablets
- Effervescent Tablets
- Capsules
- Hard Gelatin Capsules
- Soft Gelatin Capsules
- Others
- Powders & Granules
- Lozenges & Pastilles
- Gummies
- Tablets
-
By Drug Release Mechanism :
- Immediate Release
- Delayed Release
- Controlled Release
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
- Hypermarkets / Supermarkets
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa (MEA)
Table of Content
- 1. Global Market - Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Key Inclusions
- 5. Market Background
- 6. Global Market Demand (in Value US$ Bn) Analysis 2012 to 2021 and Forecast, 2022 to 2032
- 7. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
- 7.1. Tablets
- 7.1.1. Conventional/Immediate Release
- 7.1.2. Modified Release
- 7.1.3. Chewable Tablets
- 7.1.4. Effervescent Tablets
- 7.2. Capsules
- 7.2.1. Hard Gelatin Capsules
- 7.2.2. Soft Gelatin Capsules
- 7.2.3. Others
- 7.3. Powders & Granules
- 7.4. Lozenges & Pastilles
- 7.5. Gummies
- 7.1. Tablets
- 8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
- 8.1. Immediate Release
- 8.2. Delayed Release
- 8.3. Controlled Release
- 9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
- 9.1. Hospital Pharmacies
- 9.2. Retail Pharmacies
- 9.3. Drug Stores
- 9.4. Online Pharmacies
- 9.5. Hypermarkets / Supermarkets
- 10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Europe
- 10.4. South Asia
- 10.5. East Asia
- 10.6. Oceania
- 10.7. Middle East & Africa
- 11. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
- 12. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
- 13. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032
- 14. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
- 15. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
- 16. Oceania Market Analysis 2012 to 2021 and Forecast 2022 to 2032
- 17. Middle East & Africa Market Analysis 2012 to 2021 and Forecast 2022 to 2032
- 18. Market Structure Analysis
- 19. Competition Analysis
- 19.1. AstraZeneca Plc.
- 19.2. Bristol-Myers Squibb Company
- 19.3. Eli Lilly and Company
- 19.4. Gilead Sciences
- 19.5. Merck & Co. Inc
- 19.6. Novartis AG
- 19.7. Pfizer Inc.
- 19.8. AbbVie Inc.
- 19.9. Boehringer Ingelheim GmbH
- 19.10. Hoffman-La-Roche Ltd.
- 19.11. Johnson & Johnson
- 19.12. Biogen Inc.
- 19.13. Bayer AG
- 19.14. Teva Pharmaceuticals
- 19.15. Amgen Inc.
- 19.16. Takeda Pharmaceutical Company Ltd.
- 19.17. Otsuka Pharmaceutical Co., Ltd.
- 19.18. Astellas Pharma Inc.
- 20. Assumptions and Acronyms Used
- 21. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 02: Global Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 03: Global Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 04: Global Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 05: Global Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
Table 06: Global Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
Table 07: Global Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Region
Table 08: Global Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Region
Table 09: North America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 10: North America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 11: North America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 12: North America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 13: North America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 14: North America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 15: North America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
Table 16: North America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
Table 17: Latin America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 18: Latin America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 19: Latin America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 20: Latin America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 21: Latin America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 22: Latin America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 23: Latin America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
Table 24: Latin America Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
Table 25: Europe Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 26: Europe Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 27: Europe Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 28: Europe Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 29: Europe Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 30: Europe Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 31: Europe Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
Table 32: Europe Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
Table 33: South Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 34: South Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 35: South Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 36: South Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 37: South Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 38: South Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 39: South Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
Table 40: South Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
Table 41: East Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 42: East Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 43: East Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 44: East Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 45: East Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 46: East Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 47: East Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
Table 48: East Asia Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
Table 49: Oceania Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 50: Oceania Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 51: Oceania Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 52: Oceania Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 53: Oceania Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 54: Oceania Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 55: Oceania Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
Table 56: Oceania Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
Table 57: Middle East & Africa Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 58: Middle East & Africa Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 59: Middle East & Africa Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 60: Middle East & Africa Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 61: Middle East & Africa Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 62: Middle East & Africa Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release Mechanism
Table 63: Middle East & Africa Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
Table 64: Middle East & Africa Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure A: Global Market Value Share, by Dosage Form 2022 (E)
Figure B: Global Market Value Share, by Drug Release Mechanism 2022 (E)
Figure C: Global Market Value Share, by Distribution Channel 2022 (E)
Figure D: Global Market Value Share, by Region 2022 (E)
Figure 01: Global Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 02: Global Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 03: Global Market Absolute $ Opportunity Analysis, 2022 to 2032
Figure 04: Global Market Analysis by Dosage Form - 2022 & 2032
Figure 05: Global Market Y-o-Y Growth Projections by Dosage Form , 2022 to 2032
Figure 06: Global Market Attractiveness, by Dosage Form, 2022- 2032
Figure 07: Global Market Analysis by Drug Release Mechanism - 2022 & 2032
Figure 08: Global Market Y-o-Y Growth Projections by Drug Release Mechanism , 2022 to 2032
Figure 09: Global Market Attractiveness, by Drug Release Mechanism, 2022- 2032
Figure 10: Global Market Analysis by Distribution Channel - 2022 & 2032
Figure 11: Global Market Y-o-Y Growth Projections by Distribution Channel , 2022 to 2032
Figure 12: Global Market Attractiveness, by Distribution Channel, 2022- 2032
Figure 13: Global Market Analysis by Region - 2022 & 2032
Figure 14: Global Market Y-o-Y Growth Projections by Region, 2022 to 2032
Figure 15: Global Market Attractiveness, By Region, 2022 to 2032
Figure 16: North America Market Value Share, by Dosage Form 2022 (E)
Figure 17: North America Market Value Share, by Drug Release Mechanism 2022 (E)
Figure 18: North America Market Value Share, by Distribution Channel 2022 (E)
Figure 19: North America Market Value Share, by Region 2022 (E)
Figure 20: North America Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 21: North America Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 22: North America Market Attractiveness Analysis , by Country
Figure 23: North America Market Attractiveness Analysis, by Dosage Form
Figure 24: North America Market Attractiveness, by Drug Release Mechanism
Figure 25: North America Market Attractiveness, by Distribution Channel
Figure 26: U.S. Market Value Proportion Analysis, 2021
Figure 27: Global Vs. U.S Growth Comparison, 2021 to 2032
Figure 28: U.S. Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 29: U.S. Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 30: U.S. Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 31: Canada Market Value Proportion Analysis, 2021
Figure 32: Global Vs. Canada Growth Comparison, 2021 to 2032
Figure 33: Canada Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 34: Canada Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 35: Canada Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 36: Latin America Market Value Share, by Dosage Form 2022 (E)
Figure 37: Latin America Market Value Share, by Drug Release Mechanism 2022 (E)
Figure 38: Latin America Market Value Share, by Distribution Channel 2022 (E)
Figure 39: Latin America Market Value Share, by Region 2022 (E)
Figure 40: Latin America Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 41: Latin America Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 42: Latin America Market Attractiveness Analysis , by Country
Figure 43: Latin America Market Attractiveness Analysis, by Dosage Form
Figure 44: Latin America Market Attractiveness, by Drug Release Mechanism
Figure 45: Latin America Market Attractiveness, by Distribution Channel
Figure 46: Brazil Market Value Proportion Analysis, 2021
Figure 47: Global Vs. Brazil Growth Comparison, 2021 to 2032
Figure 48: Brazil Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 49: Brazil Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 50: Brazil Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 51: Mexico Market Value Proportion Analysis, 2021
Figure 52: Global Vs. Mexico Growth Comparison, 2021 to 2032
Figure 53: Mexico Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 54: Mexico Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 55: Mexico Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 56: Argentina Market Value Proportion Analysis, 2021
Figure 57: Global Vs. Argentina Growth Comparison, 2021 to 2032
Figure 58: Argentina Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 59: Argentina Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 60: Argentina Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 61: Europe Market Value Share, by Dosage Form 2022 (E)
Figure 62: Europe Market Value Share, by Drug Release Mechanism 2022 (E)
Figure 63: Europe Market Value Share, by Distribution Channel 2022 (E)
Figure 64: Europe Market Value Share, by Region 2022 (E)
Figure 65: Europe Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 66: Europe Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 67: Europe Market Attractiveness Analysis , by Country
Figure 68: Europe Market Attractiveness Analysis, by Dosage Form
Figure 69: Europe Market Attractiveness, by Drug Release Mechanism
Figure 70: Europe Market Attractiveness, by Distribution Channel
Figure 71: U.K. Market Value Proportion Analysis, 2021
Figure 72: Global Vs. U.K. Growth Comparison, 2021 to 2032
Figure 73: U.K. Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 74: U.K. Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 75: U.K. Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 76: Germany Market Value Proportion Analysis, 2021
Figure 77: Global Vs. Germany Growth Comparison, 2021 to 2032
Figure 78: Germany Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 79: Germany Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 80: Germany Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 81: Italy Market Value Proportion Analysis, 2021
Figure 82: Global Vs. Italy Growth Comparison, 2021 to 2032
Figure 83: Italy Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 84: Italy Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 85: Italy Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 86: France Market Value Proportion Analysis, 2021
Figure 87: Global Vs. France Growth Comparison, 2021 to 2032
Figure 88: France Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 89: France Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 90: France Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 91: Spain Market Value Proportion Analysis, 2021
Figure 92: Global Vs. Spain Growth Comparison, 2021 to 2032
Figure 93: Spain Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 94: Spain Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 95: Spain Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 96: BENELUX Market Value Proportion Analysis, 2021
Figure 97: Global Vs. BENELUX Growth Comparison, 2021 to 2032
Figure 98: BENELUX Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 99: BENELUX Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 100: BENELUX Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 101: Nordic Countries Market Value Proportion Analysis, 2021
Figure 102: Global Vs. Nordic Countries Growth Comparison, 2021 to 2032
Figure 103: Nordic Countries Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 104: Nordic Countries Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 105: Nordic Countries Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 106: Russia Market Value Proportion Analysis, 2021
Figure 107: Global Vs. Russia Growth Comparison, 2021 to 2032
Figure 108: Russia Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 109: Russia Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 110: Russia Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 111: South Asia Market Value Share, by Dosage Form 2022 (E)
Figure 112: South Asia Market Value Share, by Drug Release Mechanism 2022 (E)
Figure 113: South Asia Market Value Share, by Distribution Channel 2022 (E)
Figure 114: South Asia Market Value Share, by Region 2022 (E)
Figure 115: South Asia Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 116: South Asia Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 117: South Asia Market Attractiveness Analysis , by Country
Figure 118: South Asia Market Attractiveness Analysis, by Dosage Form
Figure 119: South Asia Market Attractiveness, by Drug Release Mechanism
Figure 120: South Asia Market Attractiveness, by Distribution Channel
Figure 121: India Market Value Proportion Analysis, 2021
Figure 122: Global Vs. India Growth Comparison, 2021 to 2032
Figure 123: India Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 124: India Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 125: India Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 126: Malaysia Market Value Proportion Analysis, 2021
Figure 127: Global Vs. Malaysia Growth Comparison, 2021 to 2032
Figure 128: Malaysia Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 129: Malaysia Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 130: Malaysia Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 131: Thailand Market Value Proportion Analysis, 2021
Figure 132: Global Vs. Thailand Growth Comparison, 2021 to 2032
Figure 133: Thailand Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 134: Thailand Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 135: Thailand Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 136: Indonesia Market Value Proportion Analysis, 2021
Figure 137: Global Vs. Indonesia Growth Comparison, 2021 to 2032
Figure 138: Indonesia Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 139: Indonesia Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 140: Indonesia Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 141: East Asia Market Value Share, by Dosage Form 2022 (E)
Figure 142: East Asia Market Value Share, by Drug Release Mechanism 2022 (E)
Figure 143: East Asia Market Value Share, by Distribution Channel 2022 (E)
Figure 144: East Asia Market Value Share, by Region 2022 (E)
Figure 145: East Asia Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 146: East Asia Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 147: East Asia Market Attractiveness Analysis , by Country
Figure 148: East Asia Market Attractiveness Analysis, by Dosage Form
Figure 149: East Asia Market Attractiveness, by Drug Release Mechanism
Figure 150: East Asia Market Attractiveness, by Distribution Channel
Figure 151: China Market Value Proportion Analysis, 2021
Figure 152: Global Vs. China Growth Comparison, 2021 to 2032
Figure 153: China Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 154: China Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 155: China Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 156: Japan Market Value Proportion Analysis, 2021
Figure 157: Global Vs. Japan Growth Comparison, 2021 to 2032
Figure 158: Japan Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 159: Japan Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 160: Japan Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 161: South Korea Market Value Proportion Analysis, 2021
Figure 162: Global Vs. South Korea Growth Comparison, 2021 to 2032
Figure 163: South Korea Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 164: South Korea Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 165: South Korea Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 166: Oceania Market Value Share, by Dosage Form 2022 (E)
Figure 167: Oceania Market Value Share, by Drug Release Mechanism 2022 (E)
Figure 168: Oceania Market Value Share, by Distribution Channel 2022 (E)
Figure 169: Oceania Market Value Share, by Region 2022 (E)
Figure 170: Oceania Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 171: Oceania Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 172: Oceania Market Attractiveness Analysis , by Country
Figure 173: Oceania Market Attractiveness Analysis, by Dosage Form
Figure 174: Oceania Market Attractiveness, by Drug Release Mechanism
Figure 175: Oceania Market Attractiveness, by Distribution Channel
Figure 176: Australia Market Value Proportion Analysis, 2021
Figure 177: Global Vs. Australia Growth Comparison, 2021 to 2032
Figure 178: Australia Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 179: Australia Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 180: Australia Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 181: New Zealand Market Value Proportion Analysis, 2021
Figure 182: Global Vs. New Zealand Growth Comparison, 2021 to 2032
Figure 183: New Zealand Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 184: New Zealand Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 185: New Zealand Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 186: Middle East & Africa Market Value Share, by Dosage Form 2022 (E)
Figure 187: Middle East & Africa Market Value Share, by Drug Release Mechanism 2022 (E)
Figure 188: Middle East & Africa Market Value Share, by Distribution Channel 2022 (E)
Figure 189: Middle East & Africa Market Value Share, by Region 2022 (E)
Figure 190: Middle East & Africa Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 191: Middle East & Africa Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 192: Middle East & Africa Market Attractiveness Analysis , by Country
Figure 193: Middle East & Africa Market Attractiveness Analysis, by Dosage Form
Figure 194: Middle East & Africa Market Attractiveness, by Drug Release Mechanism
Figure 195: Middle East & Africa Market Attractiveness, by Distribution Channel
Figure 196: Turkey Market Value Proportion Analysis, 2021
Figure 197: Global Vs. Turkey Growth Comparison, 2021 to 2032
Figure 198: Turkey Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 199: Turkey Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 200: Turkey Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 201: Israel Market Value Proportion Analysis, 2021
Figure 202: Global Vs. Israel Growth Comparison, 2021 to 2032
Figure 203: Israel Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 204: Israel Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 205: Israel Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 206: GCC Countries Market Value Proportion Analysis, 2021
Figure 207: Global Vs. GCC Countries Growth Comparison, 2021 to 2032
Figure 208: GCC Countries Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 209: GCC Countries Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 210: GCC Countries Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Figure 211: South Africa Market Value Proportion Analysis, 2021
Figure 212: Global Vs. South Africa Growth Comparison, 2021 to 2032
Figure 213: South Africa Market Share Analysis (%), By Dosage Form, 2021 & 2032
Figure 214: South Africa Market Share Analysis (%), By Drug Release Mechanism, 2021 & 2032
Figure 215: South Africa Market Share Analysis (%), By Distribution Channel, 2021 & 2032
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How much was the oral solid dosage pharmaceutical market valued in 2021?
The global oral solid dosage pharmaceutical market was worth US$ 524.6 billion in 2021.
What is the demand outlook for oral solid dosage pharmaceuticals?
The global market for oral solid dosage pharmaceuticals is expected to reach US$ 1.03 trillion by 2032.
At what CAGR did the market expand over the past 9 years?
Revenue from solid dosage drugs increased at 5.8% CAGR from 2012 to 2021.
Which are the top 5 countries driving demand for oral solid dosage pharmaceuticals?
The U.S., China, Japan, India, and Germany account for the most sales of oral solid dosage pharmaceuticals.
What is the U.S. oral solid dosage pharmaceutical market outlook?
The U.S. accounted for 93.6% share of the North American market in 2021.
At what percentage is demand for oral solid dosage medicines expected to register growth in Europe?
The Europe market is predicted to expand at 5.9% CAGR over the decade.
How is the market faring in South Korea and Japan?
The South Korean oral solid dosage pharmaceutical market is expected to exhibit 5.9% CAGR, while the market in Japan is set to expand faster at 6.5% CAGR through 2032.
At what percentage is demand for oral solid dosage medications expected to register growth in South Asia?
The South Asian market is predicted to expand at 7% CAGR over the forecast period.
Oral Solid Dosage Pharmaceutical Market